Brain cancer at 21 forced Matthew Zachary into the American healthcare system decades before he understood its economics, incentives, and failures. At 52, he reflects on how surviving long enough to see the whole machine clearly led to writing We the Patients.

Cancer patients increasingly absorb the financial risk of surviving disease in America. A brain cancer survivor examines how healthcare incentives, insurance design, and policy decisions shifted instability onto patients and families while institutions protect margins.

Thirty years after brain cancer, Matthew Zachary returned to the piano at Merkin Hall for MZLIVE, a night that became far more than a concert. Survivors, advocates, clinicians, and healthcare leaders confronted what survivorship actually costs and what the system still refuses to see

Mark Cuban attacks healthcare through pricing transparency and market discipline. I would attack it through patient infrastructure, legal protection, accountability, and civic power. Together, those strategies could finally begin realigning the incentives driving American healthcare.

Millions of eczema patients increasingly distrust the treatments medicine tells them to rely on. Matthew Zachary examines topical steroid withdrawal, chronic inflammation, patient distrust, and the healthcare incentives driving one of medicine’s fastest growing credibility crises

Hospitals blame insurers. Insurers blame hospitals. Patients finance the entire system through premiums, deductibles, debt, and confusion. Matthew Zachary examines the incentive structures, financial flows, and institutional dependencies that keep American healthcare expensive, opaque, and exhausting.

A ruptured brain aneurysm triggered elite emergency care that saved a life. Insurance policy still blocks preventive screening for her child. This piece explains how US healthcare pays for catastrophe and delays detection, and what must change before the next bleed.

Prior authorization persists because it works for the system that created it. This essay explains how cost control, risk management, and delay shape patient outcomes, why reform keeps falling short, and what must change to align financial incentives with timely care.

Only 0.2% of patients appeal insurance denials, yet 80% succeed. This article examines how even small increases in appeals could shift insurer behavior, raise costs, influence Wall Street expectations, and reshape the economics of American healthcare.

Women were excluded from U.S. clinical trials until 1993. That decision shaped drug safety, outcomes, and cost for decades. This essay breaks down the incentives, capital flows, and regulatory gaps that sustained it and what must change next.

Blue Cross Blue Shield settled a 2.67 billion antitrust lawsuit in 2020 after restricting competition for more than a decade. Payments begin in 2026. Six years later, customers get checks while insurers move on. Here is what happened and why it keeps happening.

UnitedHealth dropping Medicare Advantage plans for 600000 beneficiaries exposes a structural flaw in how private insurers manage public healthcare risk as costs from emergency care and specialty drugs accelerate faster than payment models can adjust.

The new bipartisan proposal to separate insurers, PBMs, and providers targets the financial structure behind rising costs and denials. This piece explains how ownership concentration reshaped care, why regulation failed, and what structural separation could change for patients.

After surviving brain cancer at 21, Matthew Zachary examines how modern healthcare policy repackages risk as freedom. From cash subsidies to math free promises, this essay exposes why consumer style healthcare fails the moment illness enters the room.